These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26699798)

  • 1. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.
    Isono N; Imai Y; Watanabe A; Moriya K; Tamura H; Inokuchi K; Asano C; Masuda M; Shimura H; Mitsuhashi K; Kazama H; Sugimori H; Motoji T; Tanaka J
    Leuk Lymphoma; 2016 Sep; 57(9):2204-7. PubMed ID: 26699798
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.
    Hasegawa T; Aisa Y; Shimazaki K; Nakazato T
    Ann Hematol; 2015 Mar; 94(3):515-7. PubMed ID: 25107463
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.
    Yamasaki S; Kohno K; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2017 Jul; 96(7):1215-1217. PubMed ID: 28447162
    [No Abstract]   [Full Text] [Related]  

  • 4. [Development of cytomegalovirus antigenemia in 3 patients with B cell lymphoma treated with bendamustine monotherapy].
    Mitsumori T; Sueki Y; Kawashima I; Yamamoto T; Nozaki Y; Nakajima K; Kirito K
    Rinsho Ketsueki; 2014 Feb; 55(2):239-43. PubMed ID: 24598192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMV Pneumonitis following Bendamustine containing Chemotherapy.
    Singhania SVK; Parikh P; Goyle S
    J Assoc Physicians India; 2017 Sep; 65(9):92-93. PubMed ID: 29313585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
    Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress of bendamustine in the treatment of B cell non-Hodgkin lymphoma].
    Zhu H; Xu W; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2015 Nov; 36(11):972-6. PubMed ID: 26632476
    [No Abstract]   [Full Text] [Related]  

  • 8. Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
    Khodarahmi I; Ghesani N
    Blood; 2017 Aug; 130(9):1174. PubMed ID: 28860327
    [No Abstract]   [Full Text] [Related]  

  • 9. Localized cytomegalovirus reactivation after radiotherapy for high-grade gastric lymphoma.
    Saga K; Fukui T; Kato Y; Komeda T; Nakase H; Watanabe N; Nishio A; Chiba T
    Gastrointest Endosc; 2007 Mar; 65(3):545-7. PubMed ID: 17321266
    [No Abstract]   [Full Text] [Related]  

  • 10. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine can severely impair T-cell immunity against cytomegalovirus.
    Hosoda T; Yokoyama A; Yoneda M; Yamamoto R; Ohashi K; Kagoo T; Ueno H; Boku S; Yano T
    Leuk Lymphoma; 2013 Jun; 54(6):1327-8. PubMed ID: 23072371
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine.
    Nishikori M; Kitano T; Kobayashi M; Hishizawa M; Kitawaki T; Kondo T; Yamashita K; Kawabata H; Kadowaki N; Takei Y; Haga H; Takaori-Kondo A
    Int J Hematol; 2015 Jul; 102(1):53-8. PubMed ID: 25833722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine reactivates latent Epstein-Barr virus.
    Fernandez SG; Miranda JJ
    Leuk Lymphoma; 2016 May; 57(5):1208-10. PubMed ID: 26371746
    [No Abstract]   [Full Text] [Related]  

  • 14. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
    Gordon MJ; Lewis LD; Brown JR; Danilov AV
    Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido.
    Tsutsumi Y; Shigematsu A; Hashino S; Tanaka J; Chiba K; Masauzi N; Kobayashi H; Kurosawa M; Iwasaki H; Morioka M; Asaka M; Imamura M
    Ann Hematol; 2009 Apr; 88(4):375-7. PubMed ID: 18726097
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
    Hitz F; Zucca E; Pabst T; Fischer N; Cairoli A; Samaras P; Caspar CB; Mach N; Krasniqi F; Schmidt A; Rothermundt C; Enoiu M; Eckhardt K; Berardi Vilei S; Rondeau S; Mey U
    Br J Haematol; 2016 Jul; 174(2):255-63. PubMed ID: 27018242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
    Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
    Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
    Olszewski AJ; Reagan JL; Castillo JJ
    Am J Hematol; 2018 Jan; 93(1):E1-E3. PubMed ID: 28960532
    [No Abstract]   [Full Text] [Related]  

  • 19. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
    Soumerai JD; Zelenetz AD; Moskowitz CH; Palomba ML; Hamlin PA; Noy A; Straus DJ; Moskowitz AJ; Younes A; Matasar MJ; Horwitz SM; Portlock CS; Konner JA; Gounder MM; Hyman DM; Voss MH; Fury MG; Gajria D; Carvajal RD; Ho AL; Beumer JH; Kiesel B; Zhang Z; Chen A; Little RF; Jarjies C; Dang TO; France F; Mishra N; Gerecitano JF
    Clin Cancer Res; 2017 Aug; 23(15):4119-4126. PubMed ID: 28314788
    [No Abstract]   [Full Text] [Related]  

  • 20. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
    Weide R; Feiten S; Friesenhahn V; Heymanns J; Kleboth K; Thomalla J; van Roye C; Köppler H
    Leuk Lymphoma; 2013 Aug; 54(8):1640-6. PubMed ID: 23151046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.